FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

<i>N</i> ashington,	D.C.	20549
---------------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

ction 1(b).			Filed									f 1934				per res		0.5
1. Name and Address of Reporting Person* <u>Kewalramani Reshma</u>					2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [ VRTX ]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  X Director 10% Owner					
(Fir	rst) (N	/liddle)			- L ' -		ı							X Officer (give title below)			Other (specify below)	
(Last) (First) (Middle)  C/O VERTEX PHARMACEUTICALS INCORPORATED					3. Date of Earliest Transaction (Month/Day/Year) 02/24/2022									CEO & President				
50 NORTHERN AVENUE						4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable					
N M.	A 0	2210											X					
(St	ate) (Z	Ľip)																
	Table	I - No	n-Deriva	tive S	Secui	rities	Acq	uired	, Dis	posed of	, or B	enefic	ially C	)wne	ed			
Date			Date	Execution Date, /Year) if any		ate,					4 and Secur Bene Owne		rities Fricially (I		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
								Code	v	Amount	(A) o (D)	Price	Ti	Transaction(s) (Instr. 3 and 4)				(111341. 4)
Common Stock 02/24/2						.022		F		7,246	D	\$227	7.86 122,842		2,842		D	
	Tal	ole II -												vnec	I			
2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execut if any	tion Date,	Code (Inst		of Deriv Secur Acqu (A) or Dispo of (D) (Instr	ative rities ired osed	6. Date Exercisable and Expiration Date (Month/Day/Year)		ate (ear)	or		t		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		Ownership Form: Direct (D) or Indirect	11. Nature of Indirect Beneficial Ownership (Instr. 4)
	nd Address of ramani Re  (Fir RTEX PHA PORATED THERN AV  (Sta Security (Insta Conversion or Exercise Price of Derivative	ramani Reshma  (First) (N RTEX PHARMACEUTICA PORATED THERN AVENUE  N MA 0  (State) (Z  Table  Security (Instr. 3)  2. Conversion or Exercise Price of Derivative (Month/Day/Year)	ramani Reshma  (First) (Middle)  RTEX PHARMACEUTICALS  PORATED  THERN AVENUE  N MA 02210  (State) (Zip)  Table I - No  Security (Instr. 3)  2. Conversion or Exercise Price of Derivative  Nand Address of Reporting Person*  (Middle)  (Zip)  Table II - No  3. Transaction Date (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)	ramani Reshma  (First) (Middle)  RTEX PHARMACEUTICALS  PORATED  THERN AVENUE  N MA 02210  (State) (Zip)  Table I - Non-Deriva  Security (Instr. 3)  2. Transact Date (Month/Day)  Conversion or Exercise Price of Derivative Pina Address of Reporting Person*  (Month/Day/Year)  (Middle)  (Zip)  Table II - Non-Deriva  3. Transaction Date (Le.g., pu	ramani Reshma  (First) (Middle)  RTEX PHARMACEUTICALS PORATED  THERN AVENUE  N MA 02210  (State) (Zip)  Table I - Non-Derivative Security (Instr. 3)  2. Transaction Date (Month/Day/Year)  2. Table II - Derivative Security (e.g., puts, catherina purished)  Table II - Derivative Security (month/Day/Year)  2. Table II - Derivative Security (month/Day/Year)  A Deemed Execution Date, if any (Month/Day/Year)  [Stock] Table II - Derivative Security (month/Day/Year)  [Stock] Table II - Derivative Security (month/Day/Year)	ramani Reshma    Conversion or Section 3	ramani Reshma  (First) (Middle)  RTEX PHARMACEUTICALS  PORATED  Table I - Non-Derivative Securities  (Month/Day/Year)  (Stace)  Table II - Derivative Securities  (e.g., puts, calls, warra  2. Issuer Name ar  VERTEX PH  MA [VRTX]  3. Date of Earliest 02/24/2022  4. If Amendment, II  2. Transaction Date (Month/Day/Year)  I Stock  Table II - Derivative Securities  (e.g., puts, calls, warra  2. Transaction Date (month/Day/Year)  3. Transaction Date (if any (Month/Day/Year)  (Month/Day/Year)  3. Transaction Date (if any (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)  Table II - Derivative Securities  (e.g., puts, calls, warra  (a) of Code (Instr. B)  Disponding the company of the compan	ramani Reshma  (First) (Middle)  RTEX PHARMACEUTICALS PORATED  THERN AVENUE  Table I - Non-Derivative Securities Acquired  (State) (Zip)  Table II - Derivative Securities Acquired  (e.g., puts, calls, warrants, (Month/Day/Year)  Tansaction Date (Month/Day/Year)  Tansaction Date (Month/Day/Year)  Security (Instr. 3)  Table II - Derivative Securities Acquired  A. If Amendment, Date of Execution Date, if any (Month/Day/Year)  Table II - Derivative Securities Acquired  A. Deemed Execution Date, if any (Month/Day/Year)  Table III - Derivative Securities Acquired  A. Transaction Code (Instr. 8)  S. Number of Derivative Securities Acquired  A. Transaction Code (Instr. 8)	or Section 30(h) of the Investment of Address of Reporting Person*  ramani Reshma  2. Issuer Name and Ticker or Tramani Reshma  (First) (Middle)  RTEX PHARMACEUTICALS PORATED  THERN AVENUE  3. Date of Earliest Transaction (02/24/2022  4. If Amendment, Date of Origin  Table I - Non-Derivative Securities Acquired  Security (Instr. 3)  2. Transaction Date (Month/Day/Year)  (Stock  Table II - Derivative Securities Acquired, If any (Month/Day/Year)  Code  Stock  Table II - Derivative Securities Acquired, If any (Month/Day/Year)  Compression or Exercise Price of Derivative Securities Acquired, If any (Month/Day/Year)  A. Deemed Execution Date, If any (Month/Day/Year)  Society (Instr. 3)  3. Transaction Code (Instr. 8)  Society (Instr. 3, 4 and 5)	or Section 30(h) of the Investment Co and Address of Reporting Person* ramani Reshma  (First) (Middle)  RTEX PHARMACEUTICALS PORATED  THERN AVENUE  N MA 02210  (State) (Zip)  Table I - Non-Derivative Securities Acquired, Dispate (Month/Day/Year)  (Month/Day/Year)  (Stock  Table II - Derivative Securities Acquired, Dispate (e.g., puts, calls, warrants, options, composition of Code (Instr. 8)  2. Transaction Date (Rooth) Date (Month/Day/Year)  (Month/Day/Year)  (Stock  Table II - Derivative Securities Acquired, Dispate (e.g., puts, calls, warrants, options, compositions)  2. Transaction Date, (Instr. 8)  Code V  Table II - Derivative Securities Acquired, Dispate (e.g., puts, calls, warrants, options, compositions)  2. Transaction Date, (Instr. 8)  Code V  Table II - Derivative Securities Acquired, Dispate (e.g., puts, calls, warrants, options, compositions)  Acquired (A) or Disposed of (D) ((Instr. 3, 4) and 5)	or Section 30(h) of the Investment Company Act of Execution Code (Instr. 8)  2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS  MA [ VRTX ]  3. Date of Earliest Transaction (Month/Day/Year)  4. If Amendment, Date of Original Filed (Month/Day/Year)  5. Stock  Table I - Non-Derivative Securities Acquired	or Section 30(h) of the Investment Company Act of 1940  and Address of Reporting Person* ramani Reshma  (First) (Middle)  RTEX PHARMACEUTICALS PORATED  THERN AVENUE  Table I - Non-Derivative Securities Acquired, Disposed of, or Be (e.g., puts, calls, warrants, options, convertible set (e.g., puts, calls, warrants, options, convertible set (Month/Day/Year)  Table II - Derivative Securities Acquired, Disposed of, or Be (e.g., puts, calls, warrants, options, convertible set (A) or Disposed of (D) (Instr. 3, 4 and 5)  A Security (Instr. 3)  Table II - Derivative Securities Acquired, Disposed of, or Be (e.g., puts, calls, warrants, options, convertible set (A) or Disposed of (D) (Instr. 3, 4 and 5)  A Securities Acquired (Disposed of (D) (Instr. 3, 4 and 5)  Table II - Derivative Securities Acquired, Disposed of (D) (Instr. 3, 4 and 5)	or Section 30(h) of the Investment Company Act of 1940  and Address of Reporting Person* ramani Reshma  (First) (Middle)  RTEX PHARMACEUTICALS PORATED  THERN AVENUE  Table I - Non-Derivative Securities Acquired, Disposed of, or Benefic Security (Instr. 3)  Description (Month/Day/Year)  (State) (Zip)  Table I - Non-Derivative Securities Acquired, Disposed of (D) (Instr. 3, 4 and 5)  Table II - Derivative Securities Acquired, Disposed of, or Beneficial (Month/Day/Year)  (Month/Day/Year)	or Section 30(h) of the Investment Company Act of 1940  Address of Reporting Person* (Grist) (Middle)  RTEX PHARMACEUTICALS ORATED  THERN AVENUE  Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Of Cage. (Month/Day/Year)  Table II - Derivative Securities Acquired, Disposed of (D) (Instr. 3, 4 and 5)  Table II - Derivative Securities Acquired, Disposed of (D) (Instr. 3)  Table II - Derivative Securities Acquired, Disposed of (D) (Instr. 3)  Table II - Derivative Securities Acquired, Disposed of (D) (Instr. 3, 4 and 5)  Table II - Derivative Securities Acquired, Disposed of (D) (Instr. 3, 4 and 5)  Table II - Derivative Securities Acquired, Disposed of (D) (Instr. 3, 4 and 5)  Table II - Derivative Securities Acquired, Disposed of (D) (Instr. 3, 4 and 5)  Table II - Derivative Securities Acquired, Disposed of (D) (Instr. 3, 4 and 5)  Table II - Derivative Securities Acquired, Disposed of (D) (Instr. 3, 4 and 4)  Table II - Derivative Securities Acquired, Disposed of (D) (D) (Instr. 3, 4 and 4)  Table II - Derivative Securities Acquired, Disposed of (D)	or Section 30(h) of the Investment Company Act of 1940  2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [ VRTX ]  2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [ VRTX ]  3. Date of Earliest Transaction (Month/Day/Year) 02/24/2022  THERN AVENUE  Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owner Security (Instr. 3)  2. Transaction Date (Month/Day/Year) (Month/Day/Year) 2. Transaction Date (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) 2. Transaction Date (Month/Day/Year)	or Section 30(ft) of the Investment Company Act of 1940  Address of Reporting Person*  (First) (Middle)  RTEX PHARMACEUTICALS  PORATED  THERN AVENUE  A If Amendment, Date of Original Filed (Month/Day/Year)  (State) (Zip)  Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned  Security (Instr. 3)  Description of Exercise (Month/Day/Year)  Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned  Security (Month/Day/Year)  Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned  Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned  Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned  Security (Month/Day/Year)  Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned  Security (Month/Day/Year)  Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned  Securities Acquired, Disposed of, or Beneficially Owned  Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned  Securities Acquired (A) or Disposed of (D) (Instr. 3 and 4)  Securities Acquired (A) or Disposed of (D) (Instr. 3 and 4)  Securities Acquired (A) or Disposed of (D) (Instr. 3 and 4)  Securities Acquired (A) or Disposed of (D) (Instr. 3 and 4)  Securities Acquired (A) or Disposed of (D) (Instr. 3 and 4)  Securities Acquired (A) or Disposed of (D) (Instr. 3 and 4)  Securities Acquired (A) or Disposed of (D) (Instr. 3 and 4)  Securities Acquired (A) or Disposed of (D)	or Section 30(h) of the Investment Company Act of 1940  Tamani Reshma  2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [ VRTX ]  3. Date of Earliest Transaction (Month/Day/Year) (State) (Zip)  Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned Following Rymon Date (Month/Day/Year)  2. Transaction Date (Month/Day/Year) (Month/Day/Year)  2. Transaction Date (Month/Day/Year) (Month/Day/Year)  2. Transaction Date (Month/Day/Year) (Month/Day/Year)  3. Date of Earliest Transaction (Month/Day/Year) (State) (Zip)  Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned Securities (Month/Day/Year)  2. Transaction Date (Month/Day/Year) (Month/Day/Year)  2. Transaction Date (Roger In Investigate Securities Acquired, Disposed of (D) (Instr. 3, 4 and S)  3. Transaction (Month/Day/Year)  4. If Amendment, Date of Original Filed (Month/Day/Year)  2. Transaction Date (Month/Day/Year)  2. Transaction (Month/Day/Year)  2. Transaction (Month/Day/Year)  2. Transaction (Date (Instr. 3) (Price of Instr. 3)  3. Transaction (Date (Instr. 3) (Price of Instr. 3)  4. Securities Acquired (A) or Disposed of (D) (Instr. 3)  5. Relationship of Reporting Per (Check all applicable)  X. Director  X. Director  X. Form filed by One Reported (Month/Day/Year)  6. Individual or Joint/Group Filing  X. Form filed by One Reported (Month/Day/Year)  8. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and B)  8. Securities Acquired (A) or Disposed of (D) (Instr. 3)  8. Price of Date (Month/Day/Year)  8. Price of Derivative Securities Se	Address of Reporting Person's ramani Reshma  2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [ VRTX ]  3. Date of Earliest Transaction (Month/Day/Year) O2/24/2022  4. If Amendment, Date of Original Filed (Month/Day/Year) (State)  (State)  7. Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned Securities (Month/Day/Year) O2/24/2022  4. If Amendment, Date of Original Filed (Month/Day/Year) O2/24/2022  5. Relationship of Reporting Person(s) to is (Check all applicable) X Director X Difficer (give title below) CEO & President  CEO & President

**Explanation of Responses:** 

Remarks:

/s/ Sabrina Yohai, Attorney-in-

\*\* Signature of Reporting Person

**Fact** 

02/28/2022

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.